secondary Pulmonary hypertension due to the Thalassemia. Other secondary pulmonary hypertension
Conditions
Interventions
Intervention 1: Group 2 patients (as Intervention) will take valsartan drug 20 mg PO daily for six months. Intervention 2: Group 1 patients (as control) will take Sildenafil drug 25 mg PO twice per d
Treatment - Drugs
Group 2 patients (as Intervention) will take valsartan drug 20 mg PO daily for six months.
Group 1 patients (as control) will take Sildenafil drug 25 mg PO twice per day for six months.
Sponsors
School of medicine- Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
10 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: thalassemia intermedia or major, age = 10 years, systolic pulmonary artery pressure = mmhg25. Exclusion criteria: Allergy to sildenafil or valsartan, incidence the side effects of drugs, no consent to continue the study, using other drugs which are in interaction with study drugs, increased NYHA function class of dyspnea
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary arterial pressure. Timepoint: begining of the study, the last day of first month and the last day of 6th month. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dyspnea. Timepoint: begining of the study, the last day of first month and the last day of 6th month. Method of measurement: NYHA function class. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Behzad Farahani
Tehran University of Medical Sciences
Outcome results
None listed